Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 6873684, 10 pages
https://doi.org/10.1155/2017/6873684
Research Article

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26

1Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
2PET & Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark
4Division of Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
5Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
6Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Correspondence should be addressed to Anna Orlova; es.uu.mehcdem.tep@avolro.anna

Received 22 April 2017; Accepted 22 June 2017; Published 10 August 2017

Academic Editor: Ralf Schirrmacher

Copyright © 2017 Bogdan Mitran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Reubi, “Old and new peptide receptor targets in cancer: Future directions,” Recent Results in Cancer Research, vol. 194, pp. 567–576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Reubi, “Peptide receptors as molecular targets for cancer diagnosis and therapy,” Endocrine Reviews, vol. 24, no. 4, pp. 389–427, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Bodei, M. Ferrari, A. Nunn et al., “177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, supplement 2, p. S221, 2007. View at Google Scholar
  4. M. Ginj, H. Zhang, B. Waser et al., “Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16436–16441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Cescato, T. Maina, B. Nock et al., “Bombesin receptor antagonists may be preferable to agonists for tumor targeting,” Journal of Nuclear Medicine, vol. 49, no. 2, pp. 318–326, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Llinares, C. Devin, O. Chaloin et al., “Syntheses and biological activities of potent bombesin receptor antagonists,” Journal of Peptide Research, vol. 53, no. 3, pp. 275–283, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Varasteh, I. Velikyan, G. Lindeberg et al., “Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging,” Bioconjugate Chemistry, vol. 24, no. 7, pp. 1144–1153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Varasteh, O. Åberg, I. Velikyan et al., “In vitro and in vivo evaluation of a18F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging,” PLoS ONE, vol. 8, no. 12, Article ID e81932, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Tolmachev and A. Orlova, “Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets,” Current Medicinal Chemistry, vol. 17, no. 24, pp. 2636–2655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Tolmachev and S. Stone-Elander, “Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods,” Biochimica et Biophysica Acta - General Subjects, vol. 1800, no. 5, pp. 487–510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Heppeler, J. P. André, I. Buschmann et al., “Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting,” Chemistry - A European Journal, vol. 14, no. 10, pp. 3026–3034, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Varasteh, B. Mitran, U. Rosenström et al., “The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26,” Nuclear Medicine and Biology, vol. 42, no. 5, pp. 446–454, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Mitran, Z. Varasteh, R. K. Selvaraju et al., “Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26,” International Journal of Oncology, vol. 48, no. 5, pp. 2124–2134, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Dam, B. B. Olsen, C. Baun, P.-F. Høilund-Carlsen, and H. Thisgaard, “In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57,” Molecular Imaging and Biology, vol. 18, no. 3, pp. 368–376, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Kelloff, P. Choyke, and D. S. Coffey, “Challenges in clinical prostate cancer: role of imaging,” American Journal of Roentgenology, vol. 192, no. 6, pp. 1455–1470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. W. C. Eckelman, M. R. Kilbourn, and C. A. Mathis, “Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!,” Nuclear Medicine and Biology, vol. 36, no. 3, pp. 235–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. P. E. N. Braad, S. B. Hansen, H. Thisgaard, and P. F. Høilund-Carlsen, “PET imaging with the non-pure positron emitters: 55Co, 86Y and 124I,” Physics in Medicine and Biology, vol. 60, no. 9, pp. 3479–3497, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Thisgaard, M. L. Olesen, and J. H. Dam, “Radiosynthesis of 55Co- and 58mCo-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 54, no. 12, pp. 758–762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Thisgaard, B. B. Olsen, J. H. Dam, P. Bollen, J. Mollenhauer, and P. F. Høilund-Carlsen, “Evaluation of cobalt-labeled octreotide analogs for molecular imaging and Auger electron-based radionuclide therapy,” Journal of Nuclear Medicine, vol. 55, no. 8, pp. 1311–1316, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Björkelund, L. Gedda, and K. Andersson, “Comparing the epidermal growth factor interaction with four different cell lines: Intriguing effects imply strong dependency of cellular context,” PLoS ONE, vol. 6, no. 1, Article ID e16536, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Maret and B. L. Vallee, “Cobalt as probe and label of proteins,” Methods in Enzymology, vol. 226, pp. 52–70, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Abiraj, R. Mansi, M.-L. Tamma et al., “Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors,” Journal of Nuclear Medicine, vol. 52, no. 12, pp. 1970–1978, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Gourni, R. Mansi, M. Jamous et al., “N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging,” Journal of Nuclear Medicine, vol. 55, no. 10, pp. 1719–1725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Varasteh and A. Orlova, “Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer® devices,” Journal of Radioanalytical and Nuclear Chemistry, vol. 304, no. 2, pp. 823–828, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Zhang, J. Schuhmacher, B. Waser et al., “DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 8, pp. 1198–1208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Koumarianou, R. Mikołajczak, D. Pawlak et al., “Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation,” Nuclear Medicine and Biology, vol. 36, no. 6, pp. 591–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Wållberg, S. Ahlgren, C. Widström, and A. Orlova, “Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395-Cys affibody molecule for targeting of HER2-expressing tumors,” Molecular Imaging and Biology, vol. 12, no. 1, pp. 54–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Maina, B. A. Nock, H. Zhang et al., “Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs,” Journal of Nuclear Medicine, vol. 46, no. 5, pp. 823–830, 2005. View at Google Scholar · View at Scopus
  29. P. Fournier, V. Dumulon-Perreault, S. Ait-Mohand et al., “Novel radiolabeled peptides for breast and prostate tumor PET imaging: 64Cu/and 68Ga/NOTA-PEG-[D-Tyr6,βAla 11,Thi13,Nle14]BBN(6-14),” Bioconjugate Chemistry, vol. 23, no. 8, pp. 1687–1693, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. R. Lane, P. Nanda, T. L. Rold et al., “Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model,” Nuclear Medicine and Biology, vol. 37, no. 7, pp. 751–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Goethals, A. Volkaert, C. Vandewielle, R. Dierckx, and N. Lameire, “55Co-EDTA for renal imaging using positron emission tomography (PET): A feasibility study,” Nuclear Medicine and Biology, vol. 27, no. 1, pp. 77–81, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. H. M. L. Jansen, J. Pruim, A. M. V. D. Vliet et al., “Visualization of damaged brain tissue after ischemic stroke with cobalt-55 positron emission tomography,” Journal of Nuclear Medicine, vol. 35, no. 3, pp. 456–460, 1994. View at Google Scholar · View at Scopus
  33. H. M. L. Jansen, A. T. M. Willemsen, L. G. F. Sinnige et al., “Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis,” Journal of the Neurological Sciences, vol. 132, no. 2, pp. 139–145, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Garousi, K. G. Andersson, J. H. Dam et al., “The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule,” Scientific Reports, vol. 7, no. 1, Article ID 5961, 2017. View at Publisher · View at Google Scholar